top cloud hosting company jaipur

MSN Labs enters into Licensing Agreement with Lilly to launch Baricitinib (BARIDOZ) in India for COVID 19

MSN Labs enters into Licensing Agreement with Lilly to launch Baricitinib (BARIDOZ) in India for COVID 19 1

MSN Labs (MSN) announced today, that they have entered into a royalty free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for COVID-19 in India.

The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 

Dr. MSN Reddy, CMD – MSN Group, commented “This Collaboration with Eli Lilly and Company is a landmark milestone in India’s fight against COVID-19 and will thus help in increasing the availability and affordability of baricitinib”.

MSN will be launching the product under the brand name BARIDOZ in two strengths 2 mg & 4mg. MSN has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house R&D and manufacturing units.

As part of the COVID treatment range, MSN has already launched FAVILOW (Favipiravir) in the strengths of 200mg, 400mg & 800mg and OSELOW (Oseltamivir) as 75 mg capsules.

Spread the love

Add a Comment